Phrixus Pharmaceuticals, Inc.
1600 Huron Parkway
Building 520, 2nd Floor
Ann Arbor, MI 48109
1 (734) 358 (dash) 9015
thomas (dot) collet (at) phrixuspharmaceuticals (dot) com
Latest News
- Phrixus Pharmaceuticals announces Phase 2 clinical trial of Poloxamer 188 NF in non-ambulatory patients with Duchenne muscular dystrophy
- Phrixus Pharmaceuticals announces the first patient with Duchenne muscular dystrophy (DMD) to meet the 15-month mark on Carmeseal-MD™ (Poloxamer 188 NF)
- FDA allows Phrixus’s IND for Carmeseal-MD™ (P-188 NF) in Duchenne muscular dystrophy (DMD)
- Carmeseal-MD™, the first disease-modifying agent for skeletal limb muscle, diaphragm and heart
- Independent study confirms hypothesized mechanism of action for Carmeseal-MD™ (P-188 NF) as membrane sealant on dystrophic cells
- Carmeseal-MD™ (P-188 NF) improves respiratory and cardiac dysfunction in dystrophic mice after subcutaneous administration
- Phrixus Pharmaceuticals Receives Services from NIH
- Phrixus Pharmaceuticals Announces European Access Program
- Phrixus Pharmaceuticals Announces SMARTT/NHLBI Award
- Phrixus Pharmaceuticals Announces Funding by DuchenneDashboard
- Phrixus Pharmaceuticals Reports Positive Preclinical Results
- Phrixus Pharmaceuticals Announces $623,000 in NIH Funding
- Phrixus Pharmaceuticals Announces $890,000 in NIH Funding